← Oncology Approval Tracker

FDA DECISION ·

Tevimbra

tislelizumab-jsgr · BeOne Medicines USA

FDA approvalNew dosing regimenEsophageal squamous cell carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adds 150 mg every two weeks or 300 mg every four weeks with platinum-containing chemotherapy as first-line treatment of adults with unresectable or metastatic ESCC with tumor PD-L1 expression of at least 1.

LAMPGEN ANALYSIS

Why it matters

The alternate dosing intervals apply to the first-line combination use, which has a different patient population from later-line monotherapy.

What research teams should watch

Check treatment line, PD-L1 result, and compatibility of infusion schedules with the selected platinum regimen.

PRIMARY RECORDS

Sources